Drug Trial Radar · NCT07951606
Safty and Efficacy of KH658 in Subjects With Diabetic Retinopathy
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Jun 2028
Study completion Jun 2032
Sponsor
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for DR could potentially reduce the treatment burden and maintain visual acuity and retinal anatomical stability
Conditions
- Diabetic Retinopathy
Interventions
KH658 Dose 1Genetic
KH658 Dose 1 suprachoriodal single injection
KH658 Dose 2Genetic
KH658 Dose 2 suprachoriodal single injection
RanibizumabDrug
Administered by intravitreal injection once a month
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants with a ≥2 steps DRSS Improvement From Baseline in Diabetic RetinopthyTime frame: At Week 52
- Proportion of Participants Developing Vision-Threatening Events (VTEs)Time frame: At Week 52
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.